Michael J Cavnar1,2, Lin Wang3, Vinod P Balachandran1, Cristina R Antonescu4, William D Tap5, Mary Keohan5, Sam Singer1, Larissa Temple1, Garrett M Nash1, Martin R Weiser1, Jose G Guillem1, Julio Garcia Aguilar1, Ronald P DeMatteo1, Philip B Paty6. 1. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Surgery, University of Kentucky, Lexington, KY, USA. 3. Department of Gastrointestinal Surgery, Peking University Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing, China. 4. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. patyp@mskcc.org.
Abstract
BACKGROUND: Approximately 5% of gastrointestinal stromal tumors (GISTs) originate in the rectum, and historically, radical resection was commonly performed. Little is known about the outcome for rectal GIST in the era of imatinib. METHODS: Using a prospectively maintained database, this study retrospectively analyzed 47 localized primary rectal GISTs treated at our center from 1982 to 2016, stratified by when imatinib became available in 2000. Overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) were analyzed by the Kaplan-Meier method. RESULTS: Rectal GISTs represented 7.1% of 663 primary GISTs. The findings showed 17 patients in the pre-imatinib era and 30 patients in the imatinib era. The two groups had similar follow-up evaluation, age, gender, Miettinen risk, and distance to the anal verge. In the imatinib era, tumors were smaller at diagnosis (median 4 vs. 5 cm; p = 0.029), and 24 of the 30 patients received perioperative imatinib. In the high-risk patients, organ preservation and negative margins were more common among the 13 patients treated with neoadjuvant imatinib than among the 21 patients treated directly with surgery. High-risk patients who received perioperative imatinib (n = 15) had greater (or nearly significantly greater) 5-year OS, DSS, local RFS, and distant RFS than those who did not (n = 19) (91, 100, 100, and 71% vs. 47, 65, 74, and 41%; p = 0.049, 0.052, 0.077, 0.051, respectively). In the imatinib era, no patient has had a local recurrence or death due to GIST. CONCLUSIONS: The use of imatinib is associated with organ preservation and improved oncologic outcome for patients with rectal GIST.
BACKGROUND: Approximately 5% of gastrointestinal stromal tumors (GISTs) originate in the rectum, and historically, radical resection was commonly performed. Little is known about the outcome for rectal GIST in the era of imatinib. METHODS: Using a prospectively maintained database, this study retrospectively analyzed 47 localized primary rectal GISTs treated at our center from 1982 to 2016, stratified by when imatinib became available in 2000. Overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) were analyzed by the Kaplan-Meier method. RESULTS: Rectal GISTs represented 7.1% of 663 primary GISTs. The findings showed 17 patients in the pre-imatinib era and 30 patients in the imatinib era. The two groups had similar follow-up evaluation, age, gender, Miettinen risk, and distance to the anal verge. In the imatinib era, tumors were smaller at diagnosis (median 4 vs. 5 cm; p = 0.029), and 24 of the 30 patients received perioperative imatinib. In the high-risk patients, organ preservation and negative margins were more common among the 13 patients treated with neoadjuvant imatinib than among the 21 patients treated directly with surgery. High-risk patients who received perioperative imatinib (n = 15) had greater (or nearly significantly greater) 5-year OS, DSS, local RFS, and distant RFS than those who did not (n = 19) (91, 100, 100, and 71% vs. 47, 65, 74, and 41%; p = 0.049, 0.052, 0.077, 0.051, respectively). In the imatinib era, no patient has had a local recurrence or death due to GIST. CONCLUSIONS: The use of imatinib is associated with organ preservation and improved oncologic outcome for patients with rectal GIST.
Authors: Martin D McCarter; Cristina R Antonescu; Karla V Ballman; Robert G Maki; Peter W T Pisters; George D Demetri; Charles D Blanke; Margaret von Mehren; Murray F Brennan; Linda McCall; David M Ota; Ronald P DeMatteo Journal: J Am Coll Surg Date: 2012-07 Impact factor: 6.113
Authors: Grace L Ma; James D Murphy; Maria E Martinez; Jason K Sicklick Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-10-02 Impact factor: 4.254
Authors: Piotr Rutkowski; Alessandro Gronchi; Peter Hohenberger; Sylvie Bonvalot; Patrick Schöffski; Sebastian Bauer; Elena Fumagalli; Pawel Nyckowski; Buu-Phuc Nguyen; Jan Martijn Kerst; Marco Fiore; Elzbieta Bylina; Mathias Hoiczyk; Annemieke Cats; Paolo G Casali; Axel Le Cesne; Jürgen Treckmann; Eberhard Stoeckle; Johannes H W de Wilt; Stefan Sleijfer; Ronald Tielen; Winette van der Graaf; Cornelis Verhoef; Frits van Coevorden Journal: Ann Surg Oncol Date: 2013-06-13 Impact factor: 5.344
Authors: D Centonze; E Pulvirenti; A Pulvirenti D'Urso; S Franco; N Cinardi; G Giannone Journal: Tech Coloproctol Date: 2013-01-30 Impact factor: 3.781
Authors: Gerardo A Vitiello; Timothy G Bowler; Mengyuan Liu; Benjamin D Medina; Jennifer Q Zhang; Nesteene J Param; Jennifer K Loo; Rachel L Goldfeder; Frederic Chibon; Ferdinand Rossi; Shan Zeng; Ronald P DeMatteo Journal: J Clin Invest Date: 2019-02-14 Impact factor: 14.808
Authors: Hamda Almaazmi; Miloslawa Stem; Brian D Lo; James P Taylor; Sandy H Fang; Bashar Safar; Jonathan E Efron; Chady Atallah Journal: J Gastrointest Surg Date: 2019-08-06 Impact factor: 3.452
Authors: Michael J Cavnar; Kenneth Seier; Christina Curtin; Vinod P Balachandran; Daniel G Coit; Sam S Yoon; Aimee M Crago; Vivian E Strong; William D Tap; Mithat Gönen; Cristina R Antonescu; Murray F Brennan; Sam Singer; Ronald P DeMatteo Journal: Ann Surg Date: 2021-01-01 Impact factor: 13.787
Authors: Michael J Cavnar; Kenneth Seier; Mithat Gönen; Christina Curtin; Vinod P Balachandran; William D Tap; Cristina R Antonescu; Sam Singer; Ronald P DeMatteo Journal: J Gastrointest Surg Date: 2020-11-09 Impact factor: 3.267